Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(62)
•••
Comment by WalkOverTheStrton Jun 02, 2020 7:01am
256 Views
Post# 31100164

RE:RE:Phase 2b Review - Medical Only

RE:RE:Phase 2b Review - Medical Only@Harvey - I think you are missingt the forest from the trees on this one..

I'd like to have you think about why you want Womac scores and then ask yourself what is 346's value proposition (why would a dr or patient want to take it over current NSAIDs? 

I'll shortcut to the thought logic and the choices.

Is 346's value prop to be:
A) better at reducing pain than current NSAIDs?
B) Better at reducing ulcers and generally be safer than current NSAIDs?

The answer is "B", and the PH2B study proved the pain aspect is on par with NSAIDs AND we know the ulcer rate is far lower that is and always was the value prop for 346...... Also I believe the LTE issue will be sorted out / on par with NSAID as they stated...

Focus on what their goal was....  Directly from Antibe's website and what 346 is trying to change:

"“Gastrointestinal damage from NSAIDs has been a clinically significant problem since first observed with aspirin, which was introduced more than 100 years ago.""

 


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities